PIETRA, DANIELA
PIETRA, DANIELA
DIPARTIMENTO DI MEDICINA MOLECOLARE
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
2017-01-01 Rumi, E; Boveri, E; Bellini, M; Pietra, D; Ferretti, Vv; Sant'Antonio, E; Cavalloni, C; Casetti, Ic; Roncoroni, E; Ciboddo, M; Benvenuti, P; Landini, B; Fugazza, E; Troletti, D; Astori, C; Cazzola, M
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms
2020-01-01 Di Buduo, Christian Andrea; Abbonante, Vittorio; Marty, Caroline; Moccia, Francesco; Rumi, Elisa; Pietra, Daniela; Soprano, Paolo Maria; Lim, Dmitry; Cattaneo, Daniele; Iurlo, Alessandra; Gianelli, Umberto; Barosi, Giovanni; Rosti, Vittorio; Plo, Isabelle; Cazzola, Mario; Balduini, Alessandra
Diagnosis and management of prefibrotic myelofibrosis.
2018-01-01 Rumi, E; Sant'Antonio, E; Boveri, E; Pietra, D; Cavalloni, C; Roncoroni, E; Astori, C; Arcaini, L
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
2016-01-01 Pietra, D.; Rumi, E.; Ferretti, V. V.; Di Buduo, C. A.; Milanesi, C.; Cavalloni, C.; Sant'Antonio, E.; Abbonante, V.; Moccia, F.; Casetti, I. C.; Bellini, M.; Renna, M. C.; Roncoroni, E.; Fugazza, E.; Astori, C.; Boveri, E.; Rosti, V.; Barosi, G.; Balduini, A.; Cazzola, M.
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation
2007-01-01 Rumi, Elisa; Passamonti, Francesco; DELLA PORTA, MATTEO GIOVANNI; Elena, Chiara; Arcaini, Luca; Vanelli, L; DEL CURTO, Cecilia; Pietra, Daniela; Boveri, Emanuela; Pascutto, Cristiana; Cazzola, Mario; Lazzarino, Mario
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
2018-01-01 Barraco, D; Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Merli, M; Pietra, D; Barbui, T; Rotunno, G; Cazzola, M; Giorgino, T; Vannucchi, Am; Passamonti, F.
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
2011-01-01 Klampfl, T; Harutyunyan, A; Berg, T; Gisslinger, B; Schalling, M; Bagienski, K; Olcaydu, D; Passamonti, Francesco; Rumi, Elisa; Pietra, Daniela; Jäger, R; Pieri, L; Guglielmelli, P; Iacobucci, I; Martinelli, G; Cazzola, Mario; Vannucchi, Am; Gisslinger, H; Kralovics, R.
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin
2014-01-01 Pietra, Daniela; Rumi, Elisa; Chiara, Milanesi; DI BUDUO, CHRISTIAN ANDREA; Bellini, Marta; Casetti, ILARIA CAROLA; Cavalloni, Chiara; Sant'Antonio, Emanuela; Abbonante, Vittorio; Renna, MARIA CONCETTA; Ferretti, VIRGINIA VALERIA; Boveri, Emanuela; Balduini, Alessandra; Pascutto, Cristiana; Cazzola, Mario
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.
2019-01-01 Schischlik, F; Jäger, R; Rosebrock, F; Hug, E; Schuster, M; Holly, R; Fuchs, E; Milosevic Feenstra, Jd; Bogner, E; Gisslinger, B; Schalling, M; Rumi, E; Pietra, D; Fischer, G; Faé, I; Vulliard, L; Menche, J; Haferlach, T; Meggendorfer, M; Stengel, A; Bock, C; Cazzola, M; Gisslinger, H; Kralovics, R.
Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning.
2020-01-01 Bridgford, Jl; Lee, Sm; Lee, Cmm; Guglielmelli, P; Rumi, E; Pietra, D; Wilcox, S; Chhabra, Y; Rubin, Af; Cazzola, M; Vannucchi, Am; Brooks, Aj; Call, Me; Call, Mj.
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.
2018-01-01 Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Pietra, D; Barbui, T; Rotunno, G; Vannucchi, Am; Passamonti, F
Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation
2006-01-01 Greco, F.; Ciana, Annarita; Pietra, Daniela; Balduini, Cesare; Minetti, Giampaolo; Torti, Mauro
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms
2019-01-01 Rumi, E; Zibellini, S; Boveri, E; Cavalloni, C; Riboni, R; Casetti, Ic; Ciboddo, M; Trotti, C; Favaron, C; Pietra, D; Candido, C; Ferretti, Vv; Cazzola, M; Arcaini, L.
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
2019-01-01 Mora, B; Rumi, E; Guglielmelli, P; Barraco, D; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Pietra, D; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Giorgino, T; Passamonti, F.
Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications
2023-01-01 Bossi, Grazia; Brazzelli, Valeria; De Amici, Mara; Pietra, Daniela; Raviola, Chiara; Naso, Matteo; Regalbuto, Corrado; Boselli, Federica; Fortina, Valeria; Marseglia, Gian Luigi
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.
2018-01-01 Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Merli, M; Pietra, D; Casalone, R; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Passamonti, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. | 1-gen-2017 | Rumi, E; Boveri, E; Bellini, M; Pietra, D; Ferretti, Vv; Sant'Antonio, E; Cavalloni, C; Casetti, Ic; Roncoroni, E; Ciboddo, M; Benvenuti, P; Landini, B; Fugazza, E; Troletti, D; Astori, C; Cazzola, M | |
| Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms | 1-gen-2020 | Di Buduo, Christian Andrea; Abbonante, Vittorio; Marty, Caroline; Moccia, Francesco; Rumi, Elisa; Pietra, Daniela; Soprano, Paolo Maria; Lim, Dmitry; Cattaneo, Daniele; Iurlo, Alessandra; Gianelli, Umberto; Barosi, Giovanni; Rosti, Vittorio; Plo, Isabelle; Cazzola, Mario; Balduini, Alessandra | |
| Diagnosis and management of prefibrotic myelofibrosis. | 1-gen-2018 | Rumi, E; Sant'Antonio, E; Boveri, E; Pietra, D; Cavalloni, C; Roncoroni, E; Astori, C; Arcaini, L | |
| Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms | 1-gen-2016 | Pietra, D.; Rumi, E.; Ferretti, V. V.; Di Buduo, C. A.; Milanesi, C.; Cavalloni, C.; Sant'Antonio, E.; Abbonante, V.; Moccia, F.; Casetti, I. C.; Bellini, M.; Renna, M. C.; Roncoroni, E.; Fugazza, E.; Astori, C.; Boveri, E.; Rosti, V.; Barosi, G.; Balduini, A.; Cazzola, M. | |
| Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation | 1-gen-2007 | Rumi, Elisa; Passamonti, Francesco; DELLA PORTA, MATTEO GIOVANNI; Elena, Chiara; Arcaini, Luca; Vanelli, L; DEL CURTO, Cecilia; Pietra, Daniela; Boveri, Emanuela; Pascutto, Cristiana; Cazzola, Mario; Lazzarino, Mario | |
| Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. | 1-gen-2018 | Barraco, D; Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Merli, M; Pietra, D; Barbui, T; Rotunno, G; Cazzola, M; Giorgino, T; Vannucchi, Am; Passamonti, F. | |
| Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression | 1-gen-2011 | Klampfl, T; Harutyunyan, A; Berg, T; Gisslinger, B; Schalling, M; Bagienski, K; Olcaydu, D; Passamonti, Francesco; Rumi, Elisa; Pietra, Daniela; Jäger, R; Pieri, L; Guglielmelli, P; Iacobucci, I; Martinelli, G; Cazzola, Mario; Vannucchi, Am; Gisslinger, H; Kralovics, R. | |
| Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin | 1-gen-2014 | Pietra, Daniela; Rumi, Elisa; Chiara, Milanesi; DI BUDUO, CHRISTIAN ANDREA; Bellini, Marta; Casetti, ILARIA CAROLA; Cavalloni, Chiara; Sant'Antonio, Emanuela; Abbonante, Vittorio; Renna, MARIA CONCETTA; Ferretti, VIRGINIA VALERIA; Boveri, Emanuela; Balduini, Alessandra; Pascutto, Cristiana; Cazzola, Mario | |
| Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. | 1-gen-2019 | Schischlik, F; Jäger, R; Rosebrock, F; Hug, E; Schuster, M; Holly, R; Fuchs, E; Milosevic Feenstra, Jd; Bogner, E; Gisslinger, B; Schalling, M; Rumi, E; Pietra, D; Fischer, G; Faé, I; Vulliard, L; Menche, J; Haferlach, T; Meggendorfer, M; Stengel, A; Bock, C; Cazzola, M; Gisslinger, H; Kralovics, R. | |
| Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. | 1-gen-2020 | Bridgford, Jl; Lee, Sm; Lee, Cmm; Guglielmelli, P; Rumi, E; Pietra, D; Wilcox, S; Chhabra, Y; Rubin, Af; Cazzola, M; Vannucchi, Am; Brooks, Aj; Call, Me; Call, Mj. | |
| Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. | 1-gen-2018 | Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Pietra, D; Barbui, T; Rotunno, G; Vannucchi, Am; Passamonti, F | |
| Rap2, but not Rap1 GTPase is expressed in human red blood cells and is involved in vesiculation | 1-gen-2006 | Greco, F.; Ciana, Annarita; Pietra, Daniela; Balduini, Cesare; Minetti, Giampaolo; Torti, Mauro | |
| Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms | 1-gen-2019 | Rumi, E; Zibellini, S; Boveri, E; Cavalloni, C; Riboni, R; Casetti, Ic; Ciboddo, M; Trotti, C; Favaron, C; Pietra, D; Candido, C; Ferretti, Vv; Cazzola, M; Arcaini, L. | |
| Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. | 1-gen-2019 | Mora, B; Rumi, E; Guglielmelli, P; Barraco, D; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Pietra, D; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Giorgino, T; Passamonti, F. | |
| Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications | 1-gen-2023 | Bossi, Grazia; Brazzelli, Valeria; De Amici, Mara; Pietra, Daniela; Raviola, Chiara; Naso, Matteo; Regalbuto, Corrado; Boselli, Federica; Fortina, Valeria; Marseglia, Gian Luigi | |
| Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. | 1-gen-2018 | Mora, B; Giorgino, T; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, Jj; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, Rt; Benevolo, G; Albano, F; Cavalloni, C; Barraco, D; Merli, M; Pietra, D; Casalone, R; Barbui, T; Rotunno, G; Cazzola, M; Vannucchi, Am; Passamonti, F. |